Literature DB >> 7351118

Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction.

C Graffner, T B Conradson, S Hofvendahl, L Rydén.   

Abstract

Tocainide is structurally related to lidocaine but may be used orally as well as intravenously. A therapeutic plasma concentration range of 25 to 45 mumole/l has been suggested. Tocainide kinetics were studied in 6 healthy subjects and 16 patients with acute myocardial infarction. There was good accordance in kinetics of healthy subjects and patients. After intravenous administration the mean t1/2 was about 14 hr, volume of distribution about 3.0 l/kg, and corrected renal clearance about 140 ml/min. An average of 35% of the dose was recovered unchanged in urine. After oral administration the absorption rate was rapid relative to the elimination rate, extent of bioavailability was complete, and the apparent volume of distribution was the same as that after intravenous injection. A dose regimen of 750 mg intravenously directly followed by 800 mg orally and subsequently 400 mg 3 times daily resulted in therapeutic plasma levels within 15 min. The plasma levels remained within the therapeutic range throughout a period of observation from 48 to 168 hr.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7351118     DOI: 10.1038/clpt.1980.10

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

1.  High-performance liquid chromatographic analysis of tocainide in human plasma.

Authors:  L Conings; N Verbeke
Journal:  Pharm Res       Date:  1985-11       Impact factor: 4.200

Review 2.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

3.  Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure.

Authors:  B MacMahon; M Bakshi; P Branagan; J G Kelly; M J Walsh
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

5.  Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction.

Authors:  D Oltmanns; A Pottage; W Endell
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 6.  Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide.

Authors:  C P Denaro; N L Benowitz
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

7.  Prophylaxis against ventricular arrhythmias in suspected acute myocardial infarction: a comparison of tocainide and disopyramide.

Authors:  R A Allen-Narker; C J Roberts; A J Marshall; S C Jordan; D W Barritt; R M Goodfellow
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

Review 9.  Tocainide. A review of its pharmacological properties and therapeutic efficacy.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.